Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Moffitt Expert Emphasizes Need to Improve Sarcoma Diagnoses

November 19th 2020

Marilyn M. Bui, MD, PhD, highlights the importance of pathology in sarcoma and how it is the cornerstone of precision medicine.

FDA Grants PTC596 Multiple Designations for Leiomyosarcoma, Glioma

November 18th 2020

November 18, 2020 - The FDA has granted a fast track designation and an orphan drug designation to the orally bioavailable small molecule tubulin-binding agent PTC596 for potential use in patients with leiomyosarcoma; the agent also received a rare pediatric disease designation and an orphan drug designation for potential use in patients with diffuse intrinsic pontine glioma.

Dr. Randall on the Evolution of Orthopedic Surgery in Sarcoma

November 16th 2020

R. Lor Randall, MD, FACS, discusses the evolution of orthopedic surgery in sarcoma.

Nivolumab/Ipilimumab Combo Is Effective, Safe in Advanced or Unresectable Angiosarcoma

November 13th 2020

November 13, 2020 - The combination of nivolumab and ipilimumab elicited an objective response rate of 25% and was found to be well tolerated in patients with advanced or unresectable angiosarcoma, according to cohort findings of the phase 2 DART trial.

Dr. Zalcberg on the Approval of Avapritinib in GIST

November 12th 2020

John Zalcberg, PhD, OAM, discusses the approval of avapritinib in gastrointestinal stromal tumor.

Dr. Abraham on Surgical Improvements in TGCT

November 5th 2020

John A. Abraham, MD, FACS, discusses surgical improvements in tenosynovial giant cell tumor.

JTCC and Georgetown’s Alliance in Cancer Research Achieves New Level With Immunotherapy Breakthrough

November 4th 2020

It was 5:00 PM on a Monday, and Andrew Pecora, MD, FACP, CPE, was just wrapping up his practice for the day when one of his nurses came to the door, asking if he could see one more patient.

Dr. Tap on Future Research Efforts in Sarcoma

November 4th 2020

William D. Tap, MD, discusses future research efforts in sarcoma.

Selinexor Significantly Improves PFS in Unresectable Dedifferentiated Liposarcoma

November 3rd 2020

Single-agent selinexor resulted in a statistically significant prolongation of progression-free survival in patients with advanced unresectable dedifferentiated liposarcoma, meeting the primary end point of the phase 3 SEAL trial.

Dr. Tap on the Rise of Precision Medicine in Sarcoma

October 30th 2020

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.

Dr. D’Amato on the Importance of Multidisciplinary Care in Sarcoma

October 30th 2020

Gina Z. D'Amato, MD, discusses the importance of multidisciplinary care in sarcoma.

Dr. Atkins on the Expanding Role of Immunotherapy in Oncology

October 30th 2020

Michael B. Atkins, MD, discusses the expanding role of immunotherapy in oncology.

Dr. Tap on the Importance of Community and Academic Collaboration in Sarcoma

October 30th 2020

William D. Tap, MD, discusses the importance of community and academic collaboration in sarcoma.

Dr. Tseng on the Goal of the TARPSWG Analysis in Retroperitoneal Sarcoma

October 27th 2020

William W. Tseng, MD, discusses the goals of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

Dr. Tap on the Evolution of Precision Medicine in Soft Tissue Sarcomas

October 27th 2020

William D. Tap, MD, discusses the evolution of precision medicine in soft tissue sarcomas.

Dr. Atkins on the Impact of Georgetown Lombardi Cancer Center Consortium on Sarcoma Treatment

October 26th 2020

Michael B. Atkins, MD, discusses the impact of the Georgetown Lombardi Cancer Center Consortium on the treatment of patients with sarcoma.

Dr. Atkins on the Importance of the Georgetown Lombardi Cancer Center Consortium

October 26th 2020

Michael B. Atkins, MD, discusses the importance of the Georgetown Lombardi Cancer Center Consortium.

Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue Sarcoma

October 23rd 2020

Alessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.

Randall Reflects on Breadth of Sarcoma Data and Beyond at MSTS Meeting

October 23rd 2020

R. Lor Randall, MD, FACS, highlights the various data presented at the annual MSTS meeting and their implications for the future of sarcoma treatment.

Dr. Schwartz on the Benefit of Dose Reduced Nivolumab/Ipilimumab in Metastatic Sarcomas

October 22nd 2020

Gary K. Schwartz, MD, discusses the benefit of dose reducing ipilimumab plus nivolumab in metastatic sarcomas.